Trials (Tartu University Hospital): Revision history

14 December 2025

• curprev 14:1014:10, 14 December 2025‎ Francine talk contribs‎ 76,927 bytes +5‎ →‎Trials: How to access undo
• curprev 13:5413:54, 14 December 2025‎ Francine talk contribs‎ 76,922 bytes +201‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 76,721 bytes +1,701‎ Update categories. undo

2 December 2025

• curprev 16:3016:30, 2 December 2025‎ Francine talk contribs‎ 75,020 bytes +7‎ No edit summary undo
• curprev 14:0114:01, 2 December 2025‎ Lucas talk contribs‎ m 75,013 bytes +11,090‎ Update categories. undo

5 November 2024

• curprev 23:3623:36, 5 November 2024‎ Victor talk contribs‎ 63,923 bytes +12‎ No edit summary undo

4 January 2024

• curprev 14:2014:20, 4 January 2024‎ Francine talk contribs‎ 63,911 bytes +3‎ No edit summary undo Tag: Manual revert
• curprev 14:2014:20, 4 January 2024‎ Francine talk contribs‎ 63,908 bytes −3‎ No edit summary undo
• curprev 14:1714:17, 4 January 2024‎ Francine talk contribs‎ 63,911 bytes +1,140‎ No edit summary undo

1 December 2023

• curprev 20:4720:47, 1 December 2023‎ Francine talk contribs‎ 62,771 bytes +62,771‎ Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to Tartu University Hospital page '''NCTID''': NCT04241185 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) '''Study Summary''': This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT a..."